How safe are new drugs? Market withdrawal of drugs approved in canada between 1990 and 2009

Open Medicine

Volumn 8, Issue 1, 2014, Pages 14-19

  Lexchin, Joel ^a,b,c  

^a YORK UNIVERSITY   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANADA; DRUG APPROVAL; DRUG MONITORING; DRUG RECALL; HUMAN; POSTMARKETING SURVEILLANCE; STANDARDS; STATISTICS AND NUMERICAL DATA; TIME;

CANADA; DRUG APPROVAL; DRUG MONITORING; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; SAFETY-BASED DRUG WITHDRAWALS; TIME FACTORS;

EID: 84900462132     PISSN: None     EISSN: 19112092     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?" Lancet 2005;365(9453):82-93.
2. Ahmad SR. Adverse drug event monitoring at the Food and Drug Administration: your report can make a difference. J Gen Intern Med 2003;18(1):57-60.
3. Lexchin J. New drugs and safety: what happened to new active substances approved in Canada between 1995 and 2010? Arch Intern Med 2012;172(21):1680-1681.
4. Lexchin J. Relationship between pharmaceutical company user fees and drug approvals in Canada and Australia: a hypothesis-generating study. Ann Pharmacother 2006;40(12):2216-2222.
5. Rawson N. New drug approval times and safety warnings in the United States and Canada, 1992-2011. J Popul Ther Clin Pharmacol 2013;20(2):e67-e81.
6. Berlin RJ. Examination of the relationship between oncology drug labeling revision frequency and FDA product categorization. Am J Public Health 2009;99(9):1693-1698.
7. Response to the recommendations to Health Canada of the coroner's jury investigation into the death of Vanessa Young. Ottawa (ON): Health Canada; 2002. Available from: www.hc-sc.gc.ca/ahc-asc/pubs/hpfb-dgpsa/death-deces_vanessa_young_sum-res-eng.php (accessed 2013 Sep 24).
8. Wiktorowicz ME, Lexchin J, Moscou K, Silversides A, Eggertson L. Keeping an eye on prescription drugs, keeping Canadians safe. Active monitoring systems for drug safety and effectiveness in Canada and internationally. Toronto (ON): Health Council of Canada; 2010.
9. Lexchin J. Drug withdrawals from the Canadian market for safety reasons, 1963-2004. CMAJ 2005;172(6):765-767.
10. ATC/DDD index 2013. Oslo (Norway): WHO Collaborating Centre for Drug Statistics Methodology; 2013. Available from: www.whocc.no/atc_ddd_index/(accessed 2013 Sep 24).
11. Sutcliffe H. Adverse drug reaction reporting-1999. Can Adverse React Newsl 2000;10(2):1-2.
12. McMorran M, Rodrigues D. Adverse reaction and incident reporting-2011. Can Adverse React Newsl 2012;22(3):3-5.
13. IMS Health report: state of the pharmaceutical industry 1998. IMS Health; 1999.
14. Top Rx drugs of 2011. Pharm Pract 2012 Feb-Mar;:48-53.
15. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287(17):2215-2220.
16. Arnardottir AH, Haaijer-Ruskamp FM, Straus SMJ, Eichler HG, de Graeff PA, Mol PGM. Additional safety risk to exceptionally approved drugs in Europe? Br J Clin Pharmacol 2011;72(3):490-499.
17. Top 50 prescribed medications, 2003. IMS Health Canada; 2004.
18. Draft guidance document - triggers for issuance of risk communication documents for marketed health products for human use. Ottawa (ON): Health Canada, Marketed Health Products Directorate, Therapeutic Effectiveness and Policy Bureau; 2007. Available from: http://publications.gc.ca/collections/collection_2007/hc-sc/H16448-2007E.pdf (accessed 2013 Sep 26).